The aim of the TRECE study was to describe treatment in patients with coronary heart disease (CHD). It was an observational, cross-sectional, multicenter study of patients who were treated in either an internal medicine (n=50) or cardiology (n=50) department, or in primary care (n=100) during 2006. The patients' health history, risk factors, and treatment were recorded, and noncardiac disease was evaluated using the Charlson index. Optimal medical treatment (OMT) was regarded as comprising combined administration of antiplatelet agents, statins, beta-blockers, and renin-angiotensin-aldosterone system blockers. In total, data on 2,897 patients were analyzed; their mean age was 67.4 years and 71.5% were male. Overall, 25.9% (95% confidence interval, 25.6-26.2) received OMT. Multivariate analysis showed that prescription of OMT was independently associated with hypertension, diabetes, current smoking, myocardial infarction, and angina. In contrast, nonprescription of OMT was associated with atrial fibrillation, chronic obstructive pulmonary disease, and a Charlson index =4. The main findings were that few CHD patients were prescribed OMT and that its prescription was determined by the presence of symptoms and comorbid conditions.

**Key words:** Optimal medical treatment. Limitations. Coronary heart disease

**INTRODUCTION**

The number of patients with coronary heart disease (CHD) is increasing and the medical treatment and management of associated risk factors can result in important prognostic improvements for these patients. Combined treatment with antiplatelet aggregators, beta-blockers, statins and renin-angiotensin-aldosterone system blockers with angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor antagonists (ARA-II) is considered to be the optimal medical treatment (OMT).
Optimal medical treatment was considered to be the joint prescription of antiplatelet aggregators, beta-blockers, statins and ACE inhibitors or AR-AII. Hypertension was considered to be controlled if it was <140/90 mm Hg or <130/80 mm Hg in diabetics. The resting heart rate (HR) was considered to be controlled if it was <70 bpm during the physical examination or on the electrocardiogram (ECG) during the office visit. Low-density lipoprotein (LDL) concentrations <100 mg/dL were accepted to represent controlled dyslipidemia. The control of diabetes mellitus was only done by glycemia levels <108 mg/dL; a baseline glycemia <100 mg/dL was considered to be controlled. The diagnosis of atrial fibrillation (AF) was only done by ECG. Chronic obstructive pulmonary disease (COPD) was recorded if a diagnosis of COPD existed on the clinical history or the patient was taking specific medication. The joint analysis of the comorbid conditions was done using the Charlson index, adapted to patients with CHD. A high comorbidity rate was considered to be a Charlson score of ≥4.

The Spanish Society of Cardiology sections on Arterial Hypertension, Ischemic Heart Disease and Clinical and Extrahospital Cardiology undertook the TRECE Study (TRatamiento de la Enfermedad Coronaria en España—Treatment of Coronary Heart Disease in Spain) in order to describe the control and prescription of the OMT of patients with CHD.

METHODS

Study Design

We undertook a descriptive, cross-sectional multicenter study involving specialists from 20 randomly selected health care areas. A total of 200 physicians took part (50 specialists in cardiology, 50 in internal medicine, and 100 primary care physicians) and 3000 consecutive patients during the first quarter of 2006; 103 patients were excluded as their data were either incomplete or contradictory. The protocol was approved by the Ethics Committee of the Hospital Universitario de San Juan, Alicante. The inclusion criteria were: a confirmed clinical diagnosis of stable chronic angina, chest pain with a positive stress test, a prior diagnosis of acute coronary syndrome, myocardial infarction, or unstable angina. The patients could have more than one of the inclusion criteria, which were obtained from the clinical history or medical records provided by the patients.

Figure 1. Control of cardiovascular risk factors according to the presence or absence of angina crisis. DM, diabetes mellitus; HR, heart rate; LDL, low-density lipoproteins; BP, blood pressure. *P* values for the comparison between the 4 groups.
blockers had a lower resting HR than those who were not receiving this treatment (67.3 bpm vs 72.8 bpm; \(P<.01\)); although only 61.4\% (95\% CI, 60.8-70) had a HR<70 bpm; no differences were found in the HR of the patients who were being treated with calcium antagonists.

### RESULTS

The characteristics of the sample are shown in Table 1. The control of the risk factors was generally poor and significantly worse in those patients who reported having angina (Figure). The patients who were receiving treatment with beta-blockers had a lower resting HR than those who were not receiving this treatment (67.3 bpm vs 72.8 bpm; \(P<.01\)), although only 61.4\% (95\% CI, 60.8-70) had a HR<70 bpm; no differences were found in the HR of the patients who were being treated with calcium antagonists.
Table 2 shows the treatments being received by the patients before and after the inclusion visit. The OMT was only being given in 25.9% (95% CI, 25.6-26.2) of the patients. The multivariate analysis, adjusted for age and sex, showed that hypertension, diabetes, heart failure, smoking, acute myocardial infarction, and angina were associated with the prescription of OMT (Table 3). AF or COPD were the main clinical limitations to the prescription of OMT; no association was found with the other clinical characteristics. The joint analysis of all the comorbid conditions showed that a Charlson score of ≥4 was related with less prescription of optimal treatment (OR=0.77; 95% CI, 0.61-0.98; P=.03). Of the patients with AF, 53% were receiving a beta-blocker, 50.2% antiplatelet aggregators and 60% anticoagulants; and of the patients with COPD, 78.2% were receiving antiplatelet aggregators, 72.7% statins and just 39.3% were receiving beta-blockers.

**DISCUSSION**

The TRECE Study shows that the control of risk factors in patients with CHD is generally poor, especially in those who have symptoms of angina pectoris; and furthermore, the prescription of the OMT was low and determined by the accompanying disorders. The sample of patients included in the TRECE Study was very similar to that of other international and national surveys. The low percentage of patients who were controlled is a constant finding in the many studies available. Our results also show that only half the patients with CHD had their resting HR controlled and that, in general clinical practice, beta-blockers achieve a poor control. The presence of noncardiac involvement is an important predictor of mortality in patients with CHD; the Charlson index is useful to identify those patients with a worse prognosis and our data demonstrate that the index identifies patients with a lower prescription of OMT.

Various reasons may explain the low compliance of OMT in the patients with CHD. A low degree of awareness of the aims of control of risk factors has been reported in Spain. The data from the TRECE Study have enabled us to identify that AF, COPD and comorbid conditions are the main limiting factors for the therapeutic implementation of OMT. Concerning AF, the underuse of antiplatelet aggregators seems to be related with the 60% anticoagulation, although the poor use of beta-blockers was also notable. Severe forms of COPD are a relative contraindication to the use of beta-blockers, though these drugs reduce the number of readmissions; the use of cardioselective beta-blockers, calcium antagonists or selective inhibitors of the sinus node If current, such as ivabradine, are effective alternatives.

**Study Limitations**

As this was a multicenter study, the collection of data was simplified and did not include the measurement of glycohemoglobin; this measurement has been reported in Spain. The data from the TRECE Study have enabled us to identify that AF, COPD and comorbid conditions are the main limiting factors for the therapeutic implementation of OMT. Concerning AF, the underuse of antiplatelet aggregators seems to be related with the 60% anticoagulation, although the poor use of beta-blockers was also notable. Severe forms of COPD are a relative contraindication to the use of beta-blockers, though these drugs reduce the number of readmissions; the use of cardioselective beta-blockers, calcium antagonists or selective inhibitors of the sinus node If current, such as ivabradine, are effective alternatives.

**References**